{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Coelho LE"],"funding":["French National Agency","ANRS MIE","NIAID NIH HHS","Brazilian Ministry of Health","Merck Sharp Dohme-Chibret"],"pagination":["ofae035"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10939434"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(3)"],"pubmed_abstract":["<h4>Background</h4>After antiretroviral therapy (ART) initiation, people with HIV (PWH) treated for tuberculosis (TB) may develop TB-associated immune reconstitution inflammatory syndrome (TB-IRIS). Integrase inhibitors, by providing a faster HIV-RNA decline than efavirenz, might increase the risk for this complication. We sought to assess incidence and determinants of TB-IRIS in PWH with TB on raltegravir- or efavirenz-based ART.<h4>Methods</h4>We conducted a secondary analysis of the Reflate TB 2 trial, which randomized ART-naive PWH on standard TB treatment, to receive raltegravir- or efavirenz-based ART. The primary objective was to evaluate the incidence of TB-IRIS. Incidence rate ratio comparing TB-IRIS incidence in each arm was calculated. Kaplan-Meier curves were used to compare TB"],"journal":["Open forum infectious diseases"],"pubmed_title":["Incidence and Predictors of Tuberculosis-associated IRIS in People With HIV Treated for Tuberculosis: Findings From Reflate TB2 Randomized Trial."],"pmcid":["PMC10939434"],"funding_grant_id":["ANRS 12300","UM1 AI069476"],"pubmed_authors":["Laureillard D","Chau GD","Cardoso SW","Veloso VG","Coelho LE","Escada R","Eholie S","De Castro N","Molina JM","Messou E","Grinsztejn B","Marcy O","Chazallon C","Timana I","Khosa C","N'takpe JB","Delaugerre C"],"additional_accession":[]},"is_claimable":false,"name":"Incidence and Predictors of Tuberculosis-associated IRIS in People With HIV Treated for Tuberculosis: Findings From Reflate TB2 Randomized Trial.","description":"<h4>Background</h4>After antiretroviral therapy (ART) initiation, people with HIV (PWH) treated for tuberculosis (TB) may develop TB-associated immune reconstitution inflammatory syndrome (TB-IRIS). Integrase inhibitors, by providing a faster HIV-RNA decline than efavirenz, might increase the risk for this complication. We sought to assess incidence and determinants of TB-IRIS in PWH with TB on raltegravir- or efavirenz-based ART.<h4>Methods</h4>We conducted a secondary analysis of the Reflate TB 2 trial, which randomized ART-naive PWH on standard TB treatment, to receive raltegravir- or efavirenz-based ART. The primary objective was to evaluate the incidence of TB-IRIS. Incidence rate ratio comparing TB-IRIS incidence in each arm was calculated. Kaplan-Meier curves were used to compare TB","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-07-16T04:16:18.653Z","creation":"2026-07-09T10:38:26.885Z"},"accession":"S-EPMC10939434","cross_references":{"pubmed":["38486816"],"doi":["10.1093/ofid/ofae035"]}}